Ownership history in Bellevue Group AG · 40 quarters on record
This page tracks every 13F SEC filing in which Bellevue Group AG reported a position in Vertex Pharmaceuticals Incorporated (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | ADDED | 681,120 | +175,315 | +34.7% | 5.85% | $308.8M | $453.36 |
| 2025 Q3 | ADDED | 505,805 | +64,195 | +14.5% | 4.12% | $198.1M | $391.64 |
| 2025 Q2 | ADDED | 441,610 | +28,539 | +6.9% | 4.33% | $196.6M | $445.20 |
| 2025 Q1 | REDUCED | 413,071 | -74,363 | -15.3% | 4.49% | $200.3M | $484.82 |
| 2024 Q4 | REDUCED | 487,434 | -83,972 | -14.7% | 3.78% | $196.3M | $402.70 |
| 2024 Q3 | REDUCED | 571,406 | -22,055 | -3.7% | 4.31% | $265.7M | $465.08 |
| 2024 Q2 | REDUCED | 593,461 | -75,289 | -11.3% | 4.52% | $278.2M | $468.72 |
| 2024 Q1 | REDUCED | 668,750 | -67,640 | -9.2% | 4.26% | $279.5M | $418.01 |
| 2023 Q4 | REDUCED | 736,390 | -266,345 | -26.6% | 4.58% | $299.6M | $406.89 |
| 2023 Q3 | REDUCED | 1,002,735 | -94,431 | -8.6% | 5.62% | $348.7M | $347.74 |
As of 2025 Q4 — sorted by position size